Processing and characterization of high strength wear resistant materials
| Full text | |
| Author(s): |
da Silva, Patricia Bento
;
Campos, Debora Leite
;
Ribeiro, Camila Maringolo
;
da Silva, Isabel Cristiane
;
Pavan, Fernando Rogerio
Total Authors: 5
|
| Document type: | Review article |
| Source: | EXPERT OPINION ON THERAPEUTIC PATENTS; v. 27, n. 3, p. 269-282, MAR 2017. |
| Web of Science Citations: | 4 |
| Abstract | |
Introduction: Tuberculosis, an infectious disease, has caused more deaths worldwide than any other single infectious disease, killing more than 1.5 million people each year; equating to 4,100 deaths a day. In the past 60years, no new drugs have been added to the first line regimen, in spite of the fact that thousands of papers have been published on drugs against tuberculosis and hundreds of drugs have received patents as new potential products. Thus, there is undoubtedly an urgent need for the deployment of new effective drugs against tuberculosis. Areas covered: This review brings to the reader the opportunity to understand the chemical and biological characteristics of all patented anti-tuberculosis drugs in North America, Europe, Japan, and Russia. The 116 patents discussed here concern new molecules in the early or advanced phase of development in the last 16years. Expert opinion: Of all 116 patents, only one developed drug, bedaquiline, is used, and then, only in specific cases. Another three drugs are in clinical studies. However, many other compounds, for which there are in vitro and in vivo studies, seem to fulfil the requisite criteria to be a new anti-tuberculosis agent. However, why are they not in use? Why were so many studies interrupted? Why is there no more news for many of these drugs? (AU) | |
| FAPESP's process: | 13/14957-5 - Research potential against tuberculosis of a new class of furoxan compounds and nanostructured compounds of the ruthenium(II) and copper (II) |
| Grantee: | Fernando Rogério Pavan |
| Support type: | Research Grants - Young Investigators Grants |